Targeting Th17 Effector Cytokines for the Treatment of Autoimmune Diseases

Arch Immunol Ther Exp (Warsz). 2015 Dec;63(6):405-14. doi: 10.1007/s00005-015-0362-x. Epub 2015 Sep 10.

Abstract

Interleukin (IL)-17-producing T cells, especially T helper (Th)17 cells, play a critical role in the pathogenesis of a variety of autoimmune inflammatory diseases. The pathogenic function of Th17 cells results from their production of Th17 effector cytokines, namely IL-17 (or IL-17A), IL-17F, IL-22 and IL-26. The importance of IL-17 has been demonstrated by antibody neutralization studies in both animal models of autoimmune diseases as well as in human clinical trials. This review highlights the current knowledge of the clinical aspects of the Th17 cytokines as well as therapeutic antibodies against IL-17, IL-17F, IL-17 receptor, IL-22, IL-26 and granulocyte macrophage colony-stimulating factor for the future treatment of autoimmune inflammatory diseases.

Keywords: Autoimmune disease; IL-17; IL-22; IL-26; Th17.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies, Blocking / therapeutic use
  • Autoimmune Diseases / immunology*
  • Autoimmune Diseases / therapy
  • Disease Models, Animal
  • Granulocyte-Macrophage Colony-Stimulating Factor / metabolism
  • Humans
  • Interleukin-17 / immunology
  • Interleukin-17 / metabolism*
  • Interleukin-22
  • Interleukins / metabolism
  • Th17 Cells / immunology*

Substances

  • Antibodies, Blocking
  • IL26 protein, human
  • Interleukin-17
  • Interleukins
  • Granulocyte-Macrophage Colony-Stimulating Factor